Latest Breaking News On - Immune stimulating antibody conjugate - Page 6 : comparemela.com

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesMemorial sloan kettering cancer centerNew yorkBiotherapeutic boltbodyPaige kellyBobt liRandall schatzmanDavid schullStern investor relations incRusso partnersAmerican society of oncologyBolt biotherapeutics incDevelopment rd expensesExchange commissionChief executiveAnticipated milestones

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersBDC-1001 administered to initial patients.

South koreaDavid schullEditha perezBiotherapeutic boltbodyPaige kellyExchange commissionBolt biotherapeutics incRusso partnersStern investor relations incImmune stimulating antibody conjugateChief medical officerAnnual reportMedia contactsInvestor relations

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

David schullPaige kellyRusso partnersBolt biotherapeutics incStern investor relations incBiotechnology conferenceImmune stimulating antibody conjugateMedia contactsInvestor relations

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

REDWOOD CITY, Calif., July 31, 2023 Bolt Biotherapeutics , a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced.

Paige kellyDavid schullRusso partnersStern investor relations incBolt biotherapeutics incBiotechnology conferenceImmune stimulating antibody conjugateMedia contactsInvestor relations

Bolt Biotherapeutics to Present at BTIG Virtual

REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel.

Paige kellyDavid schullStern investor relations incRusso partnersBolt biotherapeutics incBiotechnology conferenceImmune stimulating antibody conjugateMedia contactsInvestor relationsNasdaq boltBolt biotherapeutics